Demographic and clinical data in the study population
| Parameters | Group A (≤5 CE-MRI) | Group B (≥6 CE-MRI) | ||
|---|---|---|---|---|
| Subg. A1 (Gd-DTPA+Gd-BOPTA) | Subg. A2 (Gd-BOPTA) | Subg. B1 (Gd-DTPA+Gd-BOPTA) | Subg. B2 (Gd-BOPTA) | |
| No. of patients | 50 | 50 | ||
| 20 | 30 | 32 | 18 | |
| Age (mean) (yr) | 42.8 ± 11.35 | 40.3 ± 12.12 | ||
| 41.6 ± 9.34 | 43.7 ± 12.6 | 40.5 ± 12.2 | 39.9 ± 12.3 | |
| Sex (M/F) | 17/33 | 16/34 | ||
| 8/12 | 9/21 | 9/23 | 7/11 | |
| EDSS first MRI (mean/median) | 1.8/1 | 1.6/1 | ||
| 2.2/0.5 | 1.6/1 | 1.5/1 | 1.6/1 | |
| EDSS last MRI (mean/median) | 1.9/1 | 2.2/1.5 | ||
| 2.3/1.5 | 1.6/1 | 1.9/1.5 | 2.7/2.3 | |
| DMT | 43 | 42 | ||
| 15 | 28 | 26 | 16 | |
| Mean interval between GBCA administrations (mo) | 11.8 ± 6.28 | 9.2 ± 2.22 | ||
| 12.6 ± 7.64 | 11.2 ± 5.25 | 9.0 ± 2.17 | 9.6 ± 2.33 | |
| No. injections of L-GBCA (mean) (median) (range) | 3.6 ± 1.43, 4, 1–5 | 8.2 ± 2.25, 7, 6–15 | ||
| 3.4 ± 1.50, 4, 1–5 | 3.7 ± 1.39, 4, 1–5 | 8.9 ± 2.41, 9, 6–15 | 7 ± 1.24, 7, 6–10 | |
| Accumulated dose of L-GBCA (mean) (mL) | 52.5 ± 21.63 | 121.4 ± 38.69 | ||
| 52.0 ± 22.76 | 52.8 ± 21.22 | 132.0 ± 41.16 | 102.5 ± 25.16 | |
Note:—CE indicates contrast-enhanced; Subg., subgroup; DMT, disease-modifying therapy.